BioTalk with Rich Bendis

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Matt Gardner, Head of Life Sciences, Americas, at CBRE. With over 30 years of experience in the technology and life sciences sectors, Matt Gardner provides a comprehensive look at the latest trends and developments in the life sciences industry. Matt shares key findings from CBRE's recently released 'U.S. Life Sciences Talent Trends' report for 2024 (https://www.cbre.com/insights/books/us-life-sciences-talent-trends-2024), offering insights into what the life sciences sector can expect in the coming year. He discusses the national real estate market, highlighting the differences between office space and life science wet lab space, and emerging trends in the sector. The conversation explores the strategic importance of the BioHealth Capital Region (BHCR), consistently ranked as a top market for life sciences research talent. Matt elaborates on what makes this region crucial for CBRE and the life sciences sector as a whole. We also hear about how CBRE has contributed to the growth and development of the life sciences ecosystem in the BHCR, with Matt sharing examples of key projects and initiatives that stand out. Looking ahead, he outlines CBRE’s plans for further expanding and enhancing its presence and services in the region, highlighting upcoming projects and investments. Matt addresses the dynamic nature of the life sciences real estate market, discussing some of the biggest challenges in the BHCR and how CBRE is positioning itself to address these challenges while capitalizing on new opportunities. About Matt Gardner: Matt Gardner leads CBRE’s Advisory Life Sciences practice in the U.S., including occupier and investor leasing as well as sales. Before joining CBRE, he served as CEO and co-founder of the California Biomanufacturing Center. He has co-founded and served on the boards of multiple incubators across the U.S., including the Maryland Technology Development Center. Matt has a rich history of supporting life sciences companies and has contributed to numerous publications and NPR's Biotech Nation. Tune in to BioTalk for an informative discussion with Matt Gardner as we explore the future of life sciences real estate and talent trends, and CBRE’s pivotal role in supporting the growth of the BioHealth Capital Region.

In this episode of BioTalk with Rich Bendis, we have the honor of speaking with the U.S. Ambassador to the Republic of Tunisia, Joey R. Hood. With an impressive diplomacy and international relations background, Ambassador Hood sheds light on the vital collaboration between the U.S. and Tunisia in scientific research, innovation, and technology transfer. Host Rich Bendis is the President and CEO of BioHealth Innovation, Inc., dedicated to accelerating biohealth opportunities and fostering innovation across the BioHealth Capital Region of Maryland, Washington D.C., and Virginia….and the world. Ambassador Hood discusses the current status of U.S.-Tunisia cooperation in scientific research and technology transfer, emphasizing these areas’ critical role in Tunisia’s development. He highlights the importance of scientific research, innovation, and technology transfer in Tunisia and explains how the U.S. can support and enhance these efforts. We explore the Department of State-US funded CURES project in Tunisia, examining its goals, progress, and future objectives. Ambassador Hood elaborates on the significance of U.S. funding for projects like CURES and the broader impact on both nations. BioHealth Innovation, Inc. (BHI) is a contractor to FHI 360, supporting the CURES project to assist Tunisia in building its life science research, technology transfer, and commercialization capabilities. The conversation also covers other key partnerships and projects that the U.S. supports in Tunisia, aimed at fostering research and technology transfer. Ambassador Hood shares insights into these collaborations and his vision for the future of U.S.-Tunisia relations in science and technology. "The collaborative efforts between the U.S. and Tunisia in scientific research and technology transfer are crucial for advancing innovation and fostering economic growth. The programs we discuss on BioTalk are a testament to the great work happening in this field. I want to thank Ambassador Hood for joining us and sharing his invaluable insights on these important initiatives," says Rich Bendis. About Joey R. Hood: Joey Hood was confirmed by the U.S. Senate on December 22, 2022. He has held several leadership positions in the U.S. Department of State’s Bureau of Near Eastern Affairs, including Acting Assistant Secretary. His extensive diplomatic career includes assignments in Iraq, Kuwait, Saudi Arabia, Yemen, and Qatar. Prior to the Foreign Service, Mr. Hood was a Fulbright scholar in Burkina Faso and worked at a bank in Vermont. He earned a Master’s degree from the Fletcher School at Tufts University and a Bachelor’s degree from Dartmouth College. Tune in to BioTalk for an insightful conversation with Ambassador Joey R. Hood as we explore the dynamics of U.S.-Tunisia cooperation in science and technology, and its potential to drive innovation and progress.

Join us for an episode of BioTalk with Rich Bendis featuring Dr. Bradley Maron, Senior Associate Dean for Precision Medicine and Executive Co-Director of the University of Maryland-Institute for Health Computing at the University of Maryland School of Medicine. With his extensive background in cardiovascular research and precision medicine, Dr. Maron offers a wealth of knowledge and innovative perspectives. In this episode, Dr. Maron shares his professional journey, discussing his various roles at the University of Maryland and what drew him to the region. He provides a comparative analysis of the ecosystems in Boston/Harvard and Maryland/University of Maryland, highlighting the unique attributes and opportunities within each. Dr. Maron introduces the Institute for Health Computing (IHC), explaining its creation, mission, and strategic partnerships with the University System of Maryland and Montgomery County. He outlines the significance of data science in improving health and wellness, addressing its increasing role and challenges. We learn about the IHC’s approach to bringing learning and healthcare directly to communities, illustrated by an example of their methodology: analyze, innovate, prevent, treat, and adapt. Dr. Maron discusses how the IHC aims to become an economic driver for the University System of Maryland, the state, the BioHealth Capital Region, and the nation, fostering startups, spinouts, commercialization efforts, and entrepreneurial activities. Dr. Maron outlines the Institute’s ambitious goals for the first five years and the range of services to be provided. He also details the decision to establish the IHC in Montgomery County, describing its new facilities and the county’s supportive role. Tune in to BioTalk for an informative discussion with Dr. Bradley Maron as we explore the future of precision medicine and the impactful work of the Institute for Health Computing.

Radiological Health (CDRH) at the US Food and Drug Administration (FDA). With a distinguished background as a board-certified ophthalmologist and epidemiologist, Dr. Tarver is at the forefront of transforming the evaluation and inclusion of medical devices in underserved and underrepresented populations. In this episode, Dr. Tarver introduces the FDA and the CDRH Division, explaining the definition of a medical device by FDA standards. She discusses the creation of the Chief Transformation Officer role within the FDA, highlighting its importance and the strategic vision behind it. We explore the critical importance of diversity, equity, and inclusion (DEI) in evaluating medical devices, and how these efforts are essential for ensuring equitable healthcare for all. Dr. Tarver introduces the innovative “Home as a Health Care Hub” initiative by the FDA/CDRH, explaining its potential to revolutionize healthcare delivery. Dr. Tarver also addresses the broader transformation needed in the healthcare system to ensure no one is left behind, emphasizing the role of partnerships in achieving this goal. She delves into the role of Virtual Reality (VR) and Artificial Intelligence (AI) in making the home a central hub for healthcare, discussing this ambitious initiative’s current status, challenges, and long-term objectives. Additionally, we touch on Dr. Tarver’s impressive background, including her leadership roles within the CDRH and her academic achievements at Spelman College and Johns Hopkins University. Finally, we discuss the value of having the FDA in the BioHealth Capital Region and its impact on advancing healthcare innovation. Tune in to BioTalk for an insightful discussion with Dr. Michelle Tarver as we explore the future of medical devices, healthcare transformation, and the pivotal role of the FDA in shaping a more inclusive and innovative healthcare landscape. Dr. Michelle Tarver is a board-certified ophthalmologist and epidemiologist, serving as the Deputy Center Director for Transformation. In this role, Dr. Tarver facilitates the development, implementation, and direction of CDRH’s transformative projects and strategic initiatives. Under her leadership, CDRH is advancing efforts to include underserved and underrepresented populations in the evaluation of medical devices. Her CDRH career has included many leadership roles, including the Deputy Director of the Office of Strategic Partnerships and Technology Innovation and the Program Director of Patient Science and Engagement. Dr. Tarver received a B.S. in Biochemistry from Spelman College in Atlanta, GA and completed the M.D./Ph.D. program at The Johns Hopkins University School of Medicine and Bloomberg School of Public Health.

Join us for an enlightening episode of BioTalk with Rich Bendis as we welcome Dan Berglund, President and CEO of SSTI. With nearly four decades of experience in tech-based economic development (TBED), Dan has been a pivotal figure in shaping the landscape of innovation and entrepreneurship across the nation. In this episode, Dan shares the history and evolution of Technology Based Economic Development, discussing key initiatives in states like Ohio and Pennsylvania, and at the federal level. He highlights the importance of partnerships, detailing a compendium of state and federal cooperative technology programs that have driven progress in the field. We explore the early years of SSTI, looking into its creation, mission, and initial goals, and how it has grown to support a nationwide network dedicated to fostering tech-based economies. Dan discusses the evolution and growth of state TBED programs, and the changing role of the federal government in supporting these initiatives through agencies like STCS, OSTP, Commerce, NIST, and EDA. Dan also emphasizes the importance of private/public TBED partnerships, sharing insights into how these collaborations have bolstered economic growth and innovation. As he prepares to step down from his role after 28 years,and assume a part time role, Dan discusses the recruitment of a new CEO and reflects on SSTI's achievements, his legacy, and his vision for the organization's future. Additionally, Dan talks about Rich Bendis’s role as an original founding board member of SSTI, and his significant help in the early development of the organization. He also highlights the presence of several SSTI members in the BioHealth Capital Region. Finally, Dan outlines SSTI's current initiatives and projections for the future, offering a glimpse into the ongoing efforts to support prosperity through science, technology, innovation, and entrepreneurship. Experience an engaging discussion with Dan Berglund, a leader who has dedicated his career to advancing tech-based economic development and is now ready to embark on a new chapter. Tune in to BioTalk to gain valuable insights from one of the most influential figures in the field and learn about the future of tech-based economic development. Dan Berglund is the President and CEO of SSTI, a nonprofit organization dedicated to improving initiatives that support prosperity through science, technology, innovation and entrepreneurship. SSTI is the most comprehensive resource available for those involved in technology-based economic development. Leading SSTI since its inception in 1996, Mr. Berglund has helped SSTI develop a nationwide network of practitioners and policymakers dedicated to improving the economy through science, technology and innovation. SSTI works with this network to assist states and communities as they build tech-based economies, conduct research on best practices and trends in tech-based economic development, and encourage cooperation among and between state and federal programs. Prior to joining SSTI, Mr. Berglund worked as a consultant and for the Ohio Department of Development in a variety of positions, including Acting Deputy Director of the Division of Technological Innovation.

Chief of the Biomolecular Measurement Division at the Material Measurement Laboratory, NIST. With a distinguished career in analytical chemistry and extensive experience in biochemical sensing and bioprocess measurements, Michael leads critical initiatives to advance biotechnology and healthcare. In this episode, we delve into the pivotal role of NIST as a non-regulatory agency within the Department of Commerce, highlighting its profound impact on measurement science, gene therapy, gene editing, synthetic biology, and regenerative medicine. Michael shares insights into NIST's collaborations, including local companies like MedImmune/AstraZeneca and Novavax, and the importance of partnerships with academic institutions like the University of Maryland in driving local biotech advancements. We also explore specific technologies and standards such as gene delivery systems, the NIST Monoclonal Antibody Reference Material (NISTmAb), and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). Michael discusses the goals for future research and collaborations and reveals the next big developments we should anticipate in the biotech field. Don't miss this engaging conversation as we uncover the innovations and initiatives at NIST that are shaping the future of biotechnology and healthcare.

Join us in this episode of BioTalk with Rich Bendis as we delve into the Baltimore ecosystem with Kory Bailey, Chief Ecosystem Officer (CEO) of UpSurge Baltimore, a trailblazing organization dedicated to fostering equitable economic growth and innovation. Kory Bailey brings over a decade of leadership experience from both early-stage startups and big tech. He has emerged as a thought leader on equitable economic growth and a champion for Baltimore's tech ecosystem. As the CEO of UpSurge Baltimore, Kory is spearheading the vision for Baltimore to become the first Equitech hub globally, pioneering a new model for American innovation. In this discussion, Kory unveils UpSurge Baltimore's mission: to cultivate a thriving tech ecosystem for innovators, founders, and talent by fostering culture and connectivity and mobilizing regional and national assets around Baltimore startups. From exploring what drew him to Baltimore to discussing the evolution and unique aspects of UpSurge, Kory shares insights into the philanthropic landscape in Baltimore and initiatives like the Equitech Accelerator, Techstars, KHU, and CareFirst. He also delves into the primary challenges facing Baltimore and UpSurge's short-term goals focused on accountability, awareness, investment, and early-stage support. Join us as we envision Baltimore's future in the next five years and the pivotal role UpSurge Baltimore plays in shaping it. Tune in now to be part of the conversation driving equitable economic growth and innovation in Baltimore's tech ecosystem.

Discover the Future of Healthcare with John Sackett, Executive Vice President & COO of Adventist Healthcare, on BioTalk with Rich Bendis. In this episode, John Sackett shares his insights into the changing landscape of healthcare delivery. From his early days as an administrative assistant to his current role, John's journey offers invaluable lessons on leadership and innovation in the healthcare industry. Join us as we explore Adventist Healthcare's role in the BioHealth Capital Region (BHCR) and explore the transformative changes in healthcare delivery. Gain valuable insights into the challenges and innovations reshaping healthcare post-COVID and learn how Adventist Healthcare is leading the way in patient-centered care. In a candid and inspiring segment, John opens up about his personal journey of managing cystic fibrosis while excelling in his career. Discover the remarkable advancements in the treatment and life expectancy of CF patients, highlighting the power of innovation and resilience in overcoming adversity. Don't miss this enlightening episode as we navigate the evolving landscape of BioHealth Innovation and the BHCR Region with John Sackett, a visionary leader shaping the future of healthcare.

Join us for an engaging episode of BioTalk as we sit down with Lance Kawaguchi, Chief Executive Officer of the Cure Brain Cancer Foundation. Lance's career trajectory from global finance to non-profit leadership is as inspiring as it is impactful, driven by a personal mission to combat brain cancer following the loss of his mother. In this episode, we explore Lance's journey from senior investment banker to non-profit leader, propelled by personal loss and a vision for change. We delve into the SouthPoleTrek4Cancer initiative, spearheading a global effort to raise awareness and funds for brain and rare cancer charities, culminating in a historic journey to the South Pole. We recognize Lance's leadership achievements, including ringing the Nasdaq bell twice as a cancer charity CEO, and his success in bringing the GBM AGILE Clinical Trial Platform from the US to Australia, accelerating breakthrough research efforts. We also discuss Lance's strategic plans for growth and impact in the BioHealth Capital Region, driving forward the Cure Brain Cancer Foundation's mission. Additionally, we introduce the esteemed medical and scientific advisory committee steering the foundation's groundbreaking initiatives. Join us for an insightful discussion as we uncover Lance Kawaguchi's transformative journey and the innovative strides being made in the fight against brain cancer. Tune in to BioTalk and be inspired!

Are you prepared to discover a transformative shift in orthopedic innovation? Join us in this episode of BioTalk with Rich Bendis as step into the world of Nanochon with CEO Ben Holmes. Nanochon is leading the charge in the field of medical technology, reimagining the landscape of joint injury treatment. Their inventive implant not only restores damaged cartilage but also fosters fresh tissue growth. Utilizing cutting-edge 3-D printing technology and groundbreaking material, Nanochon's implant serves as both a resilient orthopedic load-bearing device and a scaffold for tissue regeneration. This advancement is poised to redefine patient recoveries, trim healthcare costs, and establish new benchmarks in cartilage rehabilitation. In this episode, we learn about Nanochon's beginnings, the uniqueness of their technology, the individuals constituting their team, their funding strategies, and the challenges they've overcome. Don't miss this episode as we venture into the frontier of advanced medical solutions with Nanochon. Tune in now and be part of the conversation reshaping the future of joint health.

In this episode of BioTalk with Rich Bendis, we’re joined by three guests from Solaxa: CEO & Founder Christian Walker, Chief Operating Officer Luis T. Gutierrez, Jr., and Chief Commercial Officer Jennifer Butler. Solaxa is a pioneering biotech company with a mission to revolutionize the treatment of cerebellar ataxias and acute nerve injuries caused by trauma and chemotherapy. Discover the compelling story behind Solaxa’s choice to establish its roots in Montgomery County and how the BioHealth Capital Region has played a crucial role in its growth. Learn how Solaxa’s team was assembled, including the inspiring success stories of Luis and Jennifer, both part of the BioHealth Innovation and Montgomery County Maryland’s Executive in Residence program. Hear how Solaxa is making a difference in the world of neurology with SLX-001, a drug showing immense promise in treating cerebellar ataxias. Dive into their innovative approach, including the development of their treatment for cerebellar ataxias. Additionally, discover how Solaxa’s pioneering efforts in this field provide hope for healing. Join us for an enlightening discussion on the future of neurology, innovative treatments, and the remarkable journey of Solaxa. CEO & Founder Christian Walker has focused his last twenty years pursuing the commercialization of nerve injury solutions. Christian’s fundraising experience spans raising money for start-ups, being a start-up venture capitalist, and securing significant non-dilutive financing through grants. At Christian’s prior start-ups, Christian was directly responsible for securing $11M in venture financing. While at Toucan Capital, he served as Principal of a $140 million venture capital fund focused on early-stage investments in stem cells and regenerative medicine. At Johns Hopkins and Walter Reed, he helped secure $22.5M in non-dilutive grants. Luis T. Gutierrez, Jr. serves as Chief Operating Officer of Solaxa while also serving as an Executive in Residence with BioHealth Innovation. In both roles, he leverages his 25+ years of expertise in helping novel medical technologies with scientific and clinical promise transition to becoming successful commercial enterprises. He previously served in executive roles with Veranex, Theralink Technologies, Aptiv Solutions, and Covance. Chief Commercial Officer Jennifer Butler has 25 years of broad biotechnology industry experience. Her commercial roles at MedImmune, AstraZeneca, and Innate have equipped her with a deep understanding of commercial execution at large and emerging biopharma. Notably, Jen launched Innate’s first commercial product in a rare oncology population. Jennifer also is also serving as an Executive in Residence with BioHealth Innovation.

Have you ever wondered about the true impact of Artificial Intelligence (AI) in the BioHealth industry? In this episode of BioTalk with Rich Bendis, we have the privilege of hosting Dr. Juergen Klenk, a Principal at Deloitte and a Board Member at BioHealth Innovation. Dr. Klenk brings a wealth of expertise and experience with a unique background combining formal scientific training and entrepreneurial ventures. Join us as we embark on an insightful discussion about the current state of AI in the BioHealth industry, diving deep into the realities and challenges of this cutting-edge technology. Dr. Klenk shares his interest in AI and the reasons behind its increasing prominence in the field. We explore the historical origins of the AI hype cycle and how we've reached the stage we're in today. Discover tangible examples that illustrate AI's true value, benefits, and impact in BioHealth. Dr. Klenk sheds light on the underlying key technologies that power AI and the associated challenges and risks. Looking to the future, we examine the outlook for AI in the coming months, years, and even this decade. Will the AI hype continue, or will we witness substantial breakthroughs and transformations? Dr. Klenk offers valuable insights into what organizations can and should do to ride the AI wave effectively. Don't miss this engaging conversation with Dr. Juergen Klenk as we navigate the exciting world of AI in the BioHealth industry. Tune in now to gain a deeper understanding of AI's reality and its potential to shape the future of healthcare and research.

Are you ready to dive into the world of groundbreaking biotechnology and the fight against chronic diseases? In this episode of BioTalk with Rich Bendis, we bring you an enlightening conversation with Dr. Nehal Mehta, Founder and CEO of Mobius Scientific, Inc. Dr. Mehta is not only a distinguished Professor of Medicine but also a visionary entrepreneur on a mission to revolutionize healthcare. Join us as we explore the journey of Mobius Scientific, an early-stage biotechnology company with a transformative approach. Mobius is developing cutting-edge biologic therapies targeting the root cause of chronic diseases, starting with lipid accumulation. This innovative platform has the potential to change the lives of millions suffering from debilitating conditions. Discover the remarkable story behind Mobius, from its scientific origins and unique name to Dr. Mehta's decision to venture into the world of entrepreneurship. We discuss the science and technology that sets Mobius apart, revealing its pivotal role in addressing age-related macular degeneration (AMD), a leading cause of blindness globally. Meet the exceptional team and advisors that drive Mobius forward and learn how the company secured its initial funding and gained visibility through strategic contests. Dr. Mehta shares critical milestones and future goals, providing insights into the promising future of Mobius and its mission to combat chronic diseases. Throughout the episode, we'll also explore how the BioHealth Capital Region has supported the growth and development of Mobius. Tune in now and be part of the movement to combat chronic diseases with Dr. Nehal Mehta and Mobius Scientific.

What is the dynamic synergy between pioneering science and transformative industry developments? Join us in this episode of BioTalk with Rich Bendis for a thought-provoking conversation about the work of Blackbird Laboratories. Our guest, Matt Tremblay, Ph.D., Chief Executive Officer of Blackbird Laboratories, sheds light on their role in fostering innovation within the vibrant BioHealth community of Baltimore and the wider BioHealth Capital Region. Blackbird Laboratories recently launched with a significant $100 million founding grant from The Stephen and Renee Bisciotti Foundation. This significant investment aims to bridge the gap between academic research and industry innovation, catalyzing the development of innovative companies, groundbreaking technologies, and a thriving entrepreneurial ecosystem in Baltimore, Maryland. They provide crucial support, including capital, program management, and strategic scientific and business insights, to drive the growth of the BioHealth industry. Their team of seasoned life sciences professionals operates on a value-driven model, committed to reducing the risk of groundbreaking technology for commercialization, attracting crucial investments, nurturing start-ups, and cultivating meaningful public-private partnerships. Their vision is grounded in promoting a thriving ecosystem in Baltimore that will contribute significantly to the growth of the BioHealth sector in the region. In this engaging episode, we’ll delve into a diverse range of topics: Don’t miss this insightful episode as we discuss the promising future of BioHealth with Blackbird Laboratories leading the way. Tune in now and become an integral part of the conversation shaping the BioHealth industry’s destiny.

Are you ready to explore the transformative world of MedTech and its profound impact on healthcare? Join us in this episode of BioTalk with Rich Bendis as we dive deep into medical technology with an exceptional guest, Neal Piper, Founder & CEO of Luminoah, winner of the 8th Annual BioHealth Capital Region Crab Trap. Neal Piper is the visionary behind Luminoah, a cutting-edge MedTech company dedicated to enhancing the lives of enteral nutrition patients through innovative hardware and software systems. With a background steeped in healthcare, Neal's journey from Pfizer's Neuroscience Division to his role as President of the Global Health Fellows Alumni Business Network has uniquely positioned him to drive change in the industry. But what inspired Neal to create Luminoah? In 2019, his family received a cancer diagnosis for their 3-year-old son, leading to a new reality and a pressing need for a better nutritional feeding program. Neal recognized the challenges faced by patients and caregivers, from bulky equipment to limited data sharing with physicians. That's when Luminoah was born. In this compelling episode, we explore: Don't miss this enlightening conversation as we journey into the heart of MedTech innovation with Neal Piper. Tune in now and be part of the conversation that's shaping the future of healthcare for enteral nutrition patients.

What are the latest advancements in cancer research and innovation? Join us in this episode of BioTalk with Rich Bendis as we explore the dynamic world of cancer research and technology development with our distinguished guest, Michael Weingarten, Director of the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI). Mr. Weingarten plays a pivotal role in leading a team of Program Directors managing the NCI's SBIR & STTR Programs, overseeing a substantial portfolio of $182 million in grants and contracts annually. These programs are at the forefront of NCI's efforts to drive innovation, fostering the development and commercialization of groundbreaking technologies and products for cancer prevention, diagnosis, and treatment. Explore the intersection of the BioHealth Capital Region and the NCI, understanding how collaboration and partnerships are shaping the future of cancer research and innovation. Finally, we delve into the goals for the future, highlighting the NCI's vision and commitment to advancing cancer prevention, diagnosis, and treatment through technology and innovation.

Are you curious about the world of transformative regenerative medicine and stem cell research? Are you eager to understand how Maryland champions researchers and companies in the field of stem cell and regenerative medicine? Do you want to learn more about the Maryland Stem Cell Research Fund (MSCRF)? Listen to the latest episode of BioTalk with Rich Bendis as he welcomes MSCRF Executive Director, Ruchika Nijhara, PhD. In this enlightening episode, Dr. Nijhara, a forward-thinking leader driven by her passion for advancing scientific innovation, delves into the funding mechanisms that Maryland employs to support research and development at all stages and fosters collaboration and innovation. Discover MSCRF's pivotal role in reshaping healthcare through stem cell research. Explore funding opportunities, real-world project examples, and success stories that highlight the profound impact of this research on healthcare and scientific advancements. Don't miss this captivating conversation on how MSCRF is shaping the future of scientific innovation in Maryland and beyond. Tune in now to discover more about MSCRF.

Are you interested in exploring cutting-edge autoimmune medicines? In this episode of BioTalk with Rich Bendis, we're delving deep into the world of transformative therapies with two remarkable guests, Dr. Chris Chapman and Dr. Adam Kaplin, from MyMD Pharmaceuticals. MyMD Pharmaceuticals is on a mission to make that a reality. Their lead clinical candidate, MYMD-1®, has the potential to reshape the entire field. But how does MYMD-1 work, and what sets it apart from current treatments? Join us as we unravel the science behind this revolutionary therapy and explore the potential indications and patient populations it could benefit. And that's not all. We also spotlight Supera-CBD, a novel synthetic cannabidiol with incredible potency and anti-inflammatory effects. How could this innovation change the landscape of chronic pain and anxiety management? Don't miss this episode of BioTalk with Rich Bendis as we embark on a journey into the future of autoimmune medicine with MyMD Pharmaceuticals. Tune in now and be part of the conversation.

How can patients help shape the future of scientific innovation? What's the vital role of the patient's voice in developing life-changing medicines? In this captivating episode, fresh off her thought-provoking appearance at the 9th Annual BioHealth Capital Region Forum, Dr. Theresa Podrebarac takes us on a journey through the dynamic landscape of autoimmune medicine. Dr. Podrebarac is a renowned physician scientist with a wealth of expertise in the biotech industry. As the Senior Vice President of Clinical Development at Horizon Therapeutics, she's at the forefront of bringing hope to patients with rare, autoimmune, and severe inflammatory diseases. Join us as we explore pivotal questions: Don't miss this enlightening conversation that delves into the nexus of science, patient advocacy, and innovation. Tune in now and become part of the future where patients' voices are not just heard but lead the way in shaping a brighter tomorrow. Available on all major podcasting platforms. Theresa Podrebarac, M.D., M.Sc., is a physician scientist with extensive development expertise in the biotech industry. At Horizon Therapeutics, Dr. Podrebarac leads the clinical development function dedicated to bringing medicines for rare, autoimmune and severe inflammatory diseases to patients. Prior to Horizon, Dr. Podrebarac served as chief medical officer at two biotech companies focusing on rare diseases. She was also vice president, immunology clinical development at AbbVie where she helped develop approved therapies for psoriasis and rheumatoid arthritis. At Biogen, she championed the development of tools and techniques for early clinical proof of concept in diseases including scleroderma and lupus skin disease. Dr. Podrebarac holds a master of science in immunology from the University of Ottawa and a medical doctorate degree from Western University. She completed a postdoctoral fellowship in immunology at Harvard University.

Join us for an insightful episode of BioTalk as host Rich Bendis welcomes back Rachel King, the visionary CEO of the Biotechnology Innovation Organization (BIO), bringing with her a remarkable journey spanning roles as an entrepreneur, board member, and advocate for the biotech industry. In this engaging installment, Rachel offers a glimpse into her evolution from consulting to industry, including her role as co-founder and former CEO of GlycoMimetics, Inc. (GMI). Discover the essence of BIO, its mission, and the global perspective it brings to the biotech landscape. Delve into Rachel's advocacy role and the critical issues facing the industry today, including pricing, congressional relations, and investment challenges. Gain insights into the state of the biotech industry and Rachel's projections for both the near and long term. Listen as we unravel the dynamic journey of Rachel King, a trailblazing leader in biotechnology, and gain a comprehensive perspective on the industry's present and future. Available now on all major podcasting platforms.